Is There a Role for Pharmacokinetic/Pharmacodynamic Anticoagulants?

American Heart Journal

199, 59-67

DOI: 10.1016/j.ahj.2017.10.002

Citation Report

#	Article	IF	Citations
1	Direct-Acting Oral Anticoagulants in Critically Ill Patients. Chest, 2019, 156, 604-618.	5.9	19
2	Monitoring of Low Dabigatran Concentrations: Diagnostic Performance at Clinically Relevant Decision Thresholds. Journal of Thrombosis and Thrombolysis, 2020, 49, 457-467.	2.2	9
3	Prevention and Treatment of Bleeding With Direct Oral Anticoagulants. Drugs, 2020, 80, 1293-1308.	15.5	12
4	Direct Oral Anticoagulants: Evidence and Unresolved Issues. Lancet, The, 2020, 396, 1767-1776.	96.9	180
5	Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose. Journal of the American College of Cardiology, 2020, 76, 2906-2907.	12.0	8
6	NOACs: An Emerging Class of Oral Anticoagulants-a Review Article. Future Journal of Pharmaceutical Sciences, 2020, 6, 95.	5.0	15
7	Pharmacokinetic-Pharmacodynamic Analysis' Role in Design of Phase IClinical Trials of Anticoagulant Agents: A Systematic Review. Expert Review of Clinical Pharmacology, 2020, 13, 1191-1202.	3.6	0
8	Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients. Clinical and Translational Science, 2020, 13, 777-784.	4.1	15
9	Associations Between Model-Predicted Rivaroxaban Exposure and Patient Characteristics and Efficacy and Safety Outcomes in the Treatment of Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 2020, 50, 1-11.	2.2	14
10	Associations Between Model-Predicted Rivaroxaban Exposure and Patient Characteristics and Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 2020, 50, 12-19.	2.2	9
11	Pharmacodynamics and Pharmacokinetics of Stroke Therapy. , 2021, .		1
12	Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?. TH Open, 2021, 05, e84-e88.	1.8	3
13	Is There Evidence of Benefit of Therapeutic Drug Monitoring for Direct Oral Anticoagulants?—Spinning Down the Centrifuge of Enthusiasm. Journal of Cardiovascular Pharmacology, 2021, 77, 419.	2.5	1
14	Dabigatran-Induced Nephropathy and Gastrointestinal Bleeding and Its Successful Treatment With Idarucizumab: A Case Report. Hospital Pharmacy, 2022, 57, 241-245.	1.1	3
15	Measuring Apixaban Levels in the Elderly Patient With Non-Valvular Atrial Fibrillation. International Journal of Cardiology, 2021, 335, 57-58.	3.2	0
16	Anticoagulation in Patients With Atrial Fibrillation and Active Cancer: An International Survey on Patient Management. European Journal of Preventive Cardiology, 2021, 28, 611-621.	6.1	52
17	Genetic Factors of Renin–Angiotensin System Associated With Major Bleeding for Patients Treated With Direct Oral Anticoagulants. Pharmaceutics, 2022, 14, 231.	7.5	5
18	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study. TH Open, 2022, 06, e10-e17.	1.8	6

#	Article	IF	Citations
19	The Value and Limitations of New Oral Anticoagulant Plasma Level Assessments. European Heart Journal Supplements, 2022, 24, A32-A41.	2.9	19
20	Association Between Genetic Polymorphisms and Bleeding in Patients on Direct Oral Anticoagulants. Pharmaceutics, 2022, 14, 1889.	7.5	18
21	Pharmakologische Eigenschaften mit Praxisrelevanz. Neurotransmitter, 2022, 33, 50-60.	0.0	0
22	Clinical Studies With Anticoagulants That Have Changed Clinical Practice. Seminars in Thrombosis and Hemostasis, 2023, 49, 242-254.	4.1	9
23	Direct Oral Anticoagulants in the Very Elderly. Thrombosis and Haemostasis, 2023, 123, 377-379.	4.6	10
24	Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress-Testing Renal Function Range in Real World Patients. Clinical Pharmacology and Therapeutics, 2023, 114, 362-370.	5.3	1
25	Navigating the Twilight Zone of DOAC Plasma Monitoring. Thrombosis Research, 2023, 225, 101-102.	2.9	0
26	Insights Into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults With Atrial Fibrillation: A Structured Narrative Review. Clinical Pharmacokinetics, 2023, 62, 351-373.	4.0	22
27	Impact of Perioperative Direct Oral Anticoagulant Assays: A Multicenter Cohort Study. Hospital Practice (1995), 2023, 51, 155-162.	1.2	5
28	Routine Measurement of DOAC Concentrations for Prognostication and Clinical Management in Acute Ischemic Stroke: Is It Ready for Prime Time?. European Journal of Internal Medicine, 2023, 113, 18-19.	4.2	1
29	Pharmacokinetic Drug–Drug Interactions With Direct Anticoagulants in the Management of Cancer-Associated Thrombosis. British Journal of Clinical Pharmacology, 2023, 89, 2369-2376.	3.0	15
30	Current Insights Into the Possible Role of Laboratory Monitoring of Effectiveness and Safety of Direct Oral Anticoagulants. Rational Pharmacotherapy in Cardiology, 2023, 19, 290-297.	0.6	3
31	Plasma Drug Values of DOACs in Patients Presenting With Gastrointestinal Bleeding: A Prospective Observational Study. Medicina (Lithuania), 2023, 59, 1466.	3.3	2
32	Unresolved Issues in the Use of Direct Acting Oral Anticoagulants. Expert Review of Cardiovascular Therapy, 2023, 21, 913-921.	2.7	3
33	Non-Vitamin K Antagonist Oral Anticoagulants in Differentiated Approach to the Use in Cardiological Practice: Literature Review. Ukrainian Journal of Cardiovascular Surgery, 2023, 31, 111-126.	0.2	0
34	DOACs vs Vitamin K Antagonists During Cardiac Rhythm Device Surgery: A Multicenter Propensity-Matched Study. JACC: Clinical Electrophysiology, 2024, 10, 121-132.	4.2	7
35	Construction of a Risk Scoring System Using Clinical Factors and RYR2 Polymorphisms for Bleeding Complications in Patients on Direct Oral Anticoagulants. Frontiers in Pharmacology, 2023, 14, 1290785.	5.3	3
36	Association Between Direct Oral Anticoagulant Concentrations and Clinical Outcomes: A Systematic Review and Meta-Analysis. Surgery in Practice and Science, 2023, 15, 100230.	1.1	2

#	Article	IF	Citations
37	Anticoagulants: From Chance Discovery to Structure-Based Design. Pharmacological Reviews, 2025, 77, 100037.	18.6	5
38	Outcomes and Disease Management in Patients With Atrial Fibrillation ≥80 Years: Data From a Consecutive 11-Year Real-World Registry. Journal of the American Heart Association, 2025, 14, e036832.	5.8	9
39	A Short History of Anticoagulant Therapy. Thrombosis Research, 2026, 263, 109753.	2.9	0
40	Continuation of Direct Oral Anticoagulants Versus Warfarin During Critical Illness: Bleeding and Clinical Outcomes in a Multicenter ICU Cohort. Journal of Thrombosis and Thrombolysis, 2026, .	2.2	0